SHIM
STOK icon

Stone House Investment Management’s Stoke Therapeutics STOK Stock Holding History

Stone House Investment Management’s Portfolio STOK Stock Details STOK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$16.4K Hold
500
– – ﹤0.01% 357
2026
Q1 		$16.3K Hold
500
– – ﹤0.01% 298
2025
Q4 		$15.9K Hold
500
– – ﹤0.01% 272
2025
Q3 		$11.8K Hold
500
– – ﹤0.01% 272
2025
Q2 		$5.67K Hold
500
– – ﹤0.01% 308
2025
Q1 		$3.33K Buy
+500
New +$4.66K ﹤0.01% 354
2024
Q4 		– Sell
-500
Closed -$6.14K – 306
2024
Q3 		$6.14K Hold
500
– – ﹤0.01% 257
2024
Q2 		$6.75K Hold
500
– – ﹤0.01% 255
2024
Q1 		$6.75K Buy
+500
New +$3.03K ﹤0.01% 267

Other funds holding STOK

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $866M AUM 231.68% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $86.4B AUM 59.51% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Stone House Investment Management's STOK Position: Q2 2026 in Review

Stone House Investment Management held its Stoke Therapeutics (STOK) position steady in Q2 2026 at 500 shares worth $16.4K. The position accounts for ﹤0.01% of the portfolio, ranked #357.

Stone House Investment Management first reported a position in STOK in Q1 2024 and has held it in 9 quarters since. 197 funds tracked by Wall St. Rank hold STOK as of Q2 2026.

  • Stone House Investment Management held 500 shares of Stoke Therapeutics worth $16.4K as of Q2 2026.
  • Stone House Investment Management left its Stoke Therapeutics share count unchanged in Q2 2026.
  • Stoke Therapeutics made up ﹤0.01% of Stone House Investment Management's portfolio in Q2 2026, its #357 holding.
  • Stone House Investment Management first reported a position in Stoke Therapeutics in Q1 2024 and has held it in 9 quarters since.
  • 197 funds tracked by Wall St. Rank held Stoke Therapeutics as of Q2 2026.

Based on Stone House Investment Management's 13F filing for Q2 2026, filed 5 Aug 2026.